Original Article

DR-70 as a novel diagnostic biomarker for gastric cancer

Volume 26 · Issue 6 Publish Date: November 15, 2015
Mehmet Arhan Hülya Yılmaz İbrahim K. Önal Murat Kocabıyık Harun Erdal Mehmet İbiş
Full Text PDF
DOI

Published In

Turkish Journal of Gastroenterology

Volume 26 · Issue 6

Pages: 480-483

History

Published Online: November 15, 2015

Copyright © 2015 Mehmet Arhan, Hülya Yılmaz, İbrahim K. Önal, Murat Kocabıyık, Harun Erdal, Mehmet İbiş

Mehmet Arhan
Department of Gastroenterology, Yüksek İhtisas Education and Research Hospital, Ankara
Hülya Yılmaz
Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Turkey
İbrahim K. Önal
Department of Internal Medicine, Divison of Gastroenterology, Gazi University Faculty of Medicine, Ankara, Turkey
Murat Kocabıyık
Department of Medical Biochemistry, Gazi University Faculty of Medicine, Ankara, Turkey
Harun Erdal
Department of Gastroenterology, Gazi University School of Medicine, Ankara, Turkey
Mehmet İbiş
Department of Internal Medicine, Divison of Gastroenterology, Gazi University Faculty of Medicine, Ankara, Turkey
Arhan, M., Yılmaz, H., Önal, İbrahim K., Kocabıyık, M., Erdal, H., & İbiş, M. (2015). DR-70 as a novel diagnostic biomarker for gastric cancer. Turkish Journal of Gastroenterology, 26(6), 480–483. https://doi.org/10.5152/tjg.2015.0425
Endnote/Zotero/Mendeley (RIS) BibTeX
Full Text Full Text PDF

Abstract

Abstract Background/Aims: To assess the utility of the DR-70 immunoassay in the diagnosis of gastric cancer. Materials and Methods: A total of 29 patients with histologically proven malignant gastric tumor and 29 healthy blood donors were enrolled in this study. DR-70 immunoassay was performed using an enzyme-linked immunosorbent assay kit to quantify the serum levels of fibrin degradation products. Results: The DR-70 values in patients with gastric cancer significantly differed from the values in controls (p<0.0001). Receiver operating characteristic curve analysis revealed ≥1.45 µg/mL as the best cut-off value to distinguish between patients with gastric cancer and healthy controls. The area under the receiver operating characteristic curve was 0.871. Using ≥1.45 µg/mL as the cut-off value, the DR-70 immunoassay showed a good clinical performance with a sensitivity of 82.8% and a specificity of 79.3%. The positive predictive value was 80.0%, and the negative predictive value was 82.1%. Conclusion: The DR-70 immunoassay reliably differs between gastric cancer and healthy controls, promising to become a useful cancer detection tool in clinical practice.

Most read articles by the same author(s)

1 2 > >> 
Article Info
Published In
Journal Turkish Journal of Gastroenterology
Volume / Issue Volume 26 · Issue 6
Pages 480-483
DOI 10.5152/tjg.2015.0425
History
Published Online November 15, 2015
Copyright
Copyright (c) 2015 Mehmet Arhan, Hülya Yılmaz, İbrahim K. Önal, Murat Kocabıyık, Harun Erdal, Mehmet İbiş
Affiliations
Mehmet Arhan
Department of Gastroenterology, Yüksek İhtisas Education and Research Hospital, Ankara
Hülya Yılmaz
Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Turkey
İbrahim K. Önal
Department of Internal Medicine, Divison of Gastroenterology, Gazi University Faculty of Medicine, Ankara, Turkey
Murat Kocabıyık
Department of Medical Biochemistry, Gazi University Faculty of Medicine, Ankara, Turkey
Harun Erdal
Department of Gastroenterology, Gazi University School of Medicine, Ankara, Turkey
Mehmet İbiş
Department of Internal Medicine, Divison of Gastroenterology, Gazi University Faculty of Medicine, Ankara, Turkey
Cite this Article
Arhan, M., Yılmaz, H., Önal, İbrahim K., Kocabıyık, M., Erdal, H., & İbiş, M. (2015). DR-70 as a novel diagnostic biomarker for gastric cancer. Turkish Journal of Gastroenterology, 26(6), 480–483. https://doi.org/10.5152/tjg.2015.0425
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX
Outlines